Articles By Rob Wright

31. J&J's Approach To Drug Discovery And Breakthrough Therapy 7/1/2013

    One year ago, the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law. Its most current version includes a provision that allows sponsor companies to request their drug be designated as a “breakthrough therapy.” In February, Johnson & Johnson (J&J) became only the second company (behind Vertex Pharmaceuticals) to have a drug receive this designation.

32. MedImmune's Blueprint For Building A Biologics R&D Engine 5/30/2013

    Bahija Jallal, VP of translational science for MedImmune, has some insights on how to successfully focus your biologics R&D operation to encourage, not kill the entrepreneurial spirit on which it was built.

33. Can Pharma And Biotech Companies Trust Emerging Markets To Protect IP? 5/30/2013

    How long can or should biotech and pharmaceutical companies continue to conduct business in regions where there is government-enabled IP theft?

34. Navigating Alnylam To The Brink Of A Breakthrough in RNAi 5/1/2013

    Alnylam went from a small start-up navigating through patent cliff chaos and economic turmoil to position the company toward being on the brink of a big breakthrough in RNAi science.

35. NCAA Madness And Drug Discovery Occupy March Calendars 2/27/2013

    As spring approaches, trade shows and March Madness will keep life science professionals occupied.

36. A Pricey Path To Drug Discovery 8/30/2012

    GlaxoSmithKline bought Human Genome Sciences in July, but what is it that GSK found so compelling it was willing to pay a 99% premium over HGS?

37. Africa – The Next Frontier For Novartis Clinical Development 8/1/2012

    Novartis accelerated year-over-year in the emerging market of Sub-Saharan Africa by developing the Region Group Emerging Market (GEM).

38. Pharma R&D: Part Of The Solution, Not Part Of The Problem 6/28/2012

    In pharmaceutical R&D, a more systematic analysis is part of the problem and not part of the solution because companies strayed away from their core ideologies. By Rob Wright, Chief Editor, Life Science Leader magazine

39. Serialization And The Outsourcing Decision 6/28/2012

    The wait-and-see approach to a serialization program has paid off for members of the pharmaceutical manufacturing supply chain, but experts say that approach is no longer advisable.. By Rob Wright, Life Science Leader magazine

40. GSK's Seekers Of Disruptive Innovation 6/1/2012

    John Baldoni, SVP PTS within GSK, created The Seekers, an idea generation team to stimulate disruptive innovation and serve as a catalyst for creating tipping points sooner. By Rob Wright